Neurosense Therapeutics Ltd's ROA from the fourth quarter of 2025 to the fourth quarter of 2023 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Neurosense Therapeutics Ltd's ROA in the fourth quarter of 2025?
Neurosense Therapeutics Ltd recorded a cumulative net loss of $-11 million during 12 months ending in the fourth quarter of 2025, resulting in a negative return on assets (ROA) of -305.11%.

However, within the Healthcare sector 1029 other companies had a higher return on assets. While return on assets, the total ranking has deteriorated compared to the third quarter of 2025 from to 5401.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Dec 31 2025) IV. Quarter	0 III. Quarter	0 II. Quarter	0 I. Quarter	(Dec 31 2023) IV. Quarter
Y / Y Total Assets Change	3 %	-48.78 %	-79.77 %	-72.29 %	41.96 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-11	0	0	-7	-7
Return On Assets (TTM)	-305.11 %	0 %	0 %	-121.32 %	-109.7 %
NRSN's Total Ranking	# 5401	#	#	#	# 5504
Total Assets (TTM) in million	11	1	2	1	11
Seq. Total Assets Change	1168.3 %	-47.12 %	89.09 %	-91.88 %	530.73 %
Seq. Net Income Change	-	-	-	-	-

NRSN's 5 Years Annual ROA >> Back to NRSN Management Effectiveness >> Compare NRSN ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 498
Sector	# 1030
Overall	# 5344

Return On Assets Statistics
High	Average	Low
-159.91 %	-454.86 %	-1082.2 %
(Dec 31 2022)		(Dec 31 2025)

Financial Statements
Neurosense Therapeutics Ltd's Assets	$ 11 million	NRSN's Balance sheet
Neurosense Therapeutics Ltd's Income	$ -11 million	Quarterly NRSN's Income Statement
NRSN's Income by Division		See NRSN's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2020) FY 2021
Y / Y Total Assets Change	3 %	31.71 %	-59.89 %	57.07 %	-
Total Assets in million	11	11	8	21	13
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-11	-10	-11	-12	-4
Annual Return On Assets	-99.68 %	-94.22 %	-137.11 %	-60.17 %	-30.95 %

NRSN's 5 Years Annual ROA >> Back to NRSN Management Effectiveness >> Compare NRSN ROA to its Competitors

More Return On Assets Ratios
NRSN's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
NRSN's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for NRSN's Competitors
Subscribers only: Roa for Neurosense Therapeutics Ltd's Suppliers
Subscribers only: Return On Assets for NRSN's Customers

You may also want to know
NRSN's Roi	NRSN's Inventory Turnover Ratio	NRSN's Growth Rates	NRSN's Dividend Comparisons
	NRSN's Profitability Ratios	NRSN's Asset Turnover Ratio	NRSN's Dividend Growth
NRSN's Roe	NRSN's Valuation Ratios	NRSN's Financial Strength Ratios	NRSN's Dividend Payout Ratio

Companies with similar Return On Assets at Dec 31 2025, within Healthcare Sector

ROA

Date modified: 2026-09-14T21:17:17+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.